• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Propensity-Matched Comparison of Evolut R Transcatheter Aortic Valve Implantation with Surgery in Intermediate-Risk Patients (From the SURTAVI Trial)
The Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial demonstrated the noninferiority of transcatheter aortic valve implantation (TAVI) using a self-expanding bioprosthesis to surgical aortic valve replacement (SAVR) for the primary endpoint of all-cause mortality or disabling stroke at 2 years in patients with severe, symptomatic aortic stenosis at intermediate risk for surgery.1 The majority of TAVI patients in the SURTAVI trial (84%) received the first generation CoreValve bioprosthesis (Medtronic, Minneapolis, MN).
Source: The American Journal of Cardiology - June 28, 2020 Category: Cardiology Authors: Steven J. Yakubov, Nicolas M. Van Mieghem, Michael J. Reardon, Patrick W. Serruys, Hemal Gada, Mubashir Mumtaz, G. Michael Deeb, Susheel Kodali, Isaac George, Stephan Windecker, Neal Kleiman, Stanley J. Chetcuti, Carlos Sanchez, Harold L. Dauerman, Shuzhe Source Type: research

Propensity-Matched Comparison of Evolut-R Transcatheter Aortic Valve Implantation With Surgery in Intermediate-Risk Patients (from the SURTAVI Trial)
The Surgical Replacement and Transcatheter Aortic Valve Implantation (SURTAVI) trial demonstrated the noninferiority of transcatheter aortic valve implantation (TAVI) using a self-expanding bioprosthesis to surgical aortic valve replacement (SAVR) for the primary end point of all-cause mortality or disabling stroke at 2 years in patients with severe, symptomatic aortic stenosis at intermediate risk for surgery.1 The majority of TAVI patients in the SURTAVI trial (84%) received the first generation CoreValve bioprosthesis (Medtronic, Minneapolis, Minnesota).
Source: The American Journal of Cardiology - June 28, 2020 Category: Cardiology Authors: Steven J. Yakubov, Nicolas M. Van Mieghem, Michael J. Reardon, Patrick W. Serruys, Hemal Gada, Mubashir Mumtaz, G. Michael Deeb, Susheel Kodali, Isaac George, Stephan Windecker, Neal Kleiman, Stanley J. Chetcuti, Carlos Sanchez, Harold L. Dauerman, Shuzhe Source Type: research

Meta-Analysis of Cerebral Embolic Protection During Transcatheter Aortic Valve Replacement
Transcatheter aortic valve replacement (TAVR) has evolved as an important treatment option for patients with severe symptomatic aortic stenosis. Despite advancements with device design, procedural techniques, and improved operator experience, stroke rates after TAVR have not declined( ∼2.5%), as per the recent data from the national cardiovascular database registry.1 Embolic protection devices (EPDs) were introduced to prevent embolization of thrombotic or calcified debris during TAVR. However, randomized controlled trials (RCTs) that investigated the efficacy and safety of the se devices have been underpowered for clinical endpoints.
Source: The American Journal of Cardiology - October 23, 2020 Category: Cardiology Authors: Salik Nazir, Fnu Zafrullah, Hafeez U.H. Virk, Charnjeet Singh Sandhu, Muhammad Ameen, Keerat Rai Ahuja Source Type: research

Cerebral Embolic Protection in Transcatheter Aortic Valve Replacement: A Meta-Analysis of Randomized Clinical Trials
Transcatheter aortic valve replacement (TAVR) has become a mainstay treatment option for most patients with severe symptomatic aortic stenosis. Although the majority of TAVR-related complications have decreased overtime, stroke rates remained relatively unchanged.1,2 Hence, numerous efforts have been devoted to developing effective strategies to mitigate the risk of post-TAVR strokes. We performed an updated meta-analysis to assess the efficacy and safety of cerebral embolic protection (CEP) during TAVR.
Source: The American Journal of Cardiology - November 14, 2022 Category: Cardiology Authors: Abdullah Al-Abcha, Yehia Saleh, Muhannad Abbasi, Edward El-Am, Mohamad Alkhouli Source Type: research

Pages: 1  2  3